Objective: Current intrapartum fetal monitoring technology is unable to provide physicians with an objective metric of fetal well-being, leading to degraded patient outcomes and increased litigation ...

References. 1 U.S. Food and Drug Administration. Pulse Oximeters for Medical Purposes – Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations.

Medtronic pulse oximetry tech gets FDA’s STeP designation. Medtronic said Tuesday that a technology it is developing for its pulse oximeters was accepted into the FDA’s Safer Technologies Program. The ...

Medtronic (NYSE: MDT) + announced today that the FDA accepted its new Nellcor technology into its STeP program.. The FDA Safer Technologies Program (STeP), a collaborative program, helps reduce ...